Overview

Professor Tom Bourne

ISUOG President 2020 - 2022, Virtual World Congress Technical Congress Chair 2020 and 2021, 2022 World Congress Co-Chair, Executive Committee, Finance & Risk Committee, Nominations Committee

Professor Tom Bourne was ISUOG President between 2020 and 2022 and is curently Chair in Gynaecology at Imperial College London, Hon Consultant Gynaecologist at Queen Charlottes and Chelsea hospital and Visiting Professor at KU Leuven in Belgium. He is an authority on managing early pregnancy complications, emergency gynaecology and gynaecological ultrasonography. He trained in ultrasound at Kings College Hospital in London. He subsequently worked at the University of Göteborg, Sweden as Medical Research Council visiting scientist, Hamar in Norway, and Leuven in Belgium. He was appointed senior lecturer and consultant gynaecologist at St George's University Hospital London before moving to Imperial College. He has edited seven books and published over 400 papers. He sits on the management committee of the Tommy’s National Centre for Miscarriage Research. He is medical advisor and trustee of the patient group, the Ectopic Pregnancy Trust. He is immediate Past-President of the UK Association of Early Pregnancy Units. He is co-founder and CEO of the International Ovarian Tumor Analysis (IOTA) group and sits on the steering committees of several large multicentre international trials. He is founder member of the RCOG task force on “supporting our doctors”. He is honorary fellow of the American Institute of Ultrasound in Medicine, honorary member of the Australasian Society for Ultrasound in Medicine and honorary member of the Brazilian and Hungarian Ultrasound Societies.

His principal research interest is diagnostics in early pregnancy and gynaecology including the IOTA, IETA, IDEA and MUSA studies, microbiome, metabolomics, novel biomarkers, and AI. His interests include the psychology of pregnancy loss and physician welfare including studies with the BMA and RCOG.

Country: UK

Language: English

Field: Gynaecology

Specialties: Early Pregnancy Care, Emergency Gynaecology, Ultrasound in Oncology, Gynaecological Ultrasonography, Physician Wellbeing

Selected Notable Publications:

Sporadic miscarriage: evidence to provide effective care. Coomarasamy A, Gallos ID, Papadopoulou A, Dhillon-Smith RK, Al-Memar M, Brewin J, Christiansen OB, Stephenson MD, Oladapo OT, Wijeyaratne CN, Small R, Bennett PR, Regan L, Goddijn M, Devall AJ, Bourne T, Brosens JJ, Quenby S.

Lancet. 2021 May 1;397(10285):1668-1674. doi: 10.1016/S0140-6736(21)00683-8. Epub 2021 Apr 27.

Validation of models to diagnose ovarian cancer in patients managed surgically or conservatively: multicentre cohort study.

Van Calster B, Valentin L, Froyman W, Landolfo C, Ceusters J, Testa AC, Wynants L, Sladkevicius P, Van Holsbeke C, Domali E, Fruscio R, Epstein E, Franchi D, Kudla MJ, Chiappa V, Alcazar JL, Leone FPG, Buonomo F, Coccia ME, Guerriero S, Deo N, Jokubkiene L, Savelli L, Fischerová D, Czekierdowski A, Kaijser J, Coosemans A, Scambia G, Vergote I, Bourne T, Timmerman D.

BMJ. 2020 Jul 30;370:m2614. doi: 10.1136/bmj.m2614.

Posttraumatic stress, anxiety and depression following miscarriage and ectopic pregnancy: a multicenter, prospective, cohort study.

Farren J, Jalmbrant M, Falconieri N, Mitchell-Jones N, Bobdiwala S, Al-Memar M, Tapp S, Van Calster B, Wynants L, Timmerman D, Bourne T.

Am J Obstet Gynecol. 2020 Apr; 222(4):367.e1-367.e22. doi: 10.1016/j.ajog.2019.10.102.

Risk of complications in patients with conservatively managed ovarian tumours (IOTA5): a 2-year interim analysis of a multicentre, prospective, cohort study.

Froyman W, Landolfo C, De Cock B, Wynants L, Sladkevicius P, Testa AC, Van Holsbeke C, Domali E, Fruscio R, Epstein E, Dos Santos Bernardo MJ, Franchi D, Kudla MJ, Chiappa V, Alcazar JL, Leone FPG, Buonomo F, Hochberg L, Coccia ME, Guerriero S, Deo N, Jokubkiene L, Kaijser J, Coosemans A, Vergote I, Verbakel JY, Bourne T, Van Calster B, Valentin L, Timmerman D.

Lancet Oncol. 2019 Mar; 20(3): 448-458. doi: 10.1016/S1470-2045(18)30837-4.

Defining safe criteria to diagnose miscarriage: prospective observational multicentre study. Preisler J, Kopeika J, Ismail L, Vathanan V, Farren J, Abdallah Y, Battacharjee P, Van Holsbeke C, Bottomley C, Gould D, Johnson S, Stalder C, Van Calster B, Hamilton J, Timmerman D, Bourne T.

BMJ. 2015 Sep 23; 351:h4579. doi: 10.1136/bmj.h4579.

Evaluating the risk of ovarian cancer before surgery using the ADNEX model to differentiate between benign, borderline, early and advanced stage invasive, and secondary metastatic tumours: prospective multicentre diagnostic studies. Van Calster B, Van Hoorde K, Valentin L, Testa AC, Fischerova D, Van Holsbeke C, Savelli L, Franchi D, Epstein E, Kaijser J, Van Belle V, Czekierdowski A, Guerriero S, Fruscio R, Lanzani C, Scala F, Bourne T, Timmerman D; International Ovarian Tumour Analysis Group.

BMJ. 2014 Oct 15;349:g5920. doi: 10.1136/bmj.g5920.

Diagnostic criteria for nonviable pregnancy early in the first trimester. Doubilet PM, Benson CB, Bourne T, Blaivas M; Society of Radiologists in Ultrasound Multispecialty Panel on Early First Trimester Diagnosis of Miscarriage and Exclusion of a Viable Intrauterine Pregnancy, Barnhart KT, Benacerraf BR, Brown DL, Filly RA, Fox JC, Goldstein SR, Kendall JL, Lyons EA, Porter MB, Pretorius DH, Timor-Tritsch IE.

N Engl J Med. 2013 Oct 10; 369(15): 1443-51. doi: 10.1056/NEJMra1302417.

Limitations of current definitions of miscarriage using mean gestational sac diameter and crown-rump length measurements: a multicenter observational study. Abdallah Y, Daemen A, Kirk E, Pexsters A, Naji O, Stalder C, Gould D, Ahmed S, Guha S, Syed S, Bottomley C, Timmerman D, Bourne T.

Ultrasound Obstet Gynecol. 2011 Nov; 38(5): 497-502. doi: 10.1002/uog.10109.

He is President of the UK Association of Early Pregnancy Units (AEPU), Trustee of the Ectopic Pregnancy Trust and on the steering committee of the International Ovarian Tumor Analysis (IOTA) trial.

1999 Gold Medal Award article

Prof. Kypros Nicolaides is Professor of Fetal Medicine at King’s College Hospital, London. He was born in Cyprus and studied medicine at Kings, training in obstetrics and gynecology and specialising in fetal medicine. He has carried out extensive research in many aspects of fetal diagnosis and therapy leading to the publication of more than 1400 peer-reviewed papers in scientific journals. His research publications on imaging and prenatal diagnosis have transformed ultrasound practice and his work to implement quality control for nuchal translucency has led to this technique becoming an established screening test of Down's syndrome and other genetic conditions. He was awarded the ISUOG Ian Donald Gold Medal in 1999 in recognition of his outstanding contribution to the field.

He has provided training in fetal medicine to more than 500 doctors from 50 countries and has supervised more than 50 doctors to undertake research leading to PhDs and MDs. In 1995 he founded the charity The Fetal Medicine Foundation, which has donated more than £45 million to promote research and training in fetal medicine throughout the world.

Professor Arri Coomarasamy is the Director of Tommy’s National Centre for Miscarriage Research and an NIHR Senior Investigator, with specialist teams in Birmingham, Coventry and London, putting patient priorities at the heart of efforts to tackle the widespread and devastating condition of early pregnancy loss. He also leads researchers at the forefront of reproductive medicine and international efforts to reduce maternal mortality. His portfolio includes numerous national and international multicentre randomised controlled trials, including EMOTIVE (Early detection and treatment of post-partum hemorrhage using the MOTIVE bundle: a World Health Organization cluster randomized trial with health economic analysis), the PROMISE trial (the role of progesterone in women with unexplained recurrent miscarriages), the TABLET trial (levothyroxine therapy for women with thyroid antibodies), the PRISM trial (progesterone therapy for women with early pregnancy bleeding), the RESPONSE trial (G-CSF treatment for recurrent miscarriage), the AIMS trial (the effects of prophylactic antibiotics before miscarriage surgery in low-income countries), the WHO CHAMPION trial (the role of carbetocin to prevent postpartum haemorrhage), the MifeMiso trial (mifepristone plus misoprostol for the management of missed miscarriage) and LOCI (A 2x2 factorial design trial of letrozole versus clomiphene and metformin versus placebo for ovulation induction in women with polycystic ovary syndrome). Consequently he was recently recognised as the “Investigator of the Year” among the NIHR Clinical Research Network for the West Midlands. Professor Coomarasamy has published over 200 medical articles in high impact journals such as NEJM and the Lancet. He serves or has in the past served on several national and international committees including RCOG clinical studies groups in Early Pregnancy and Reproductive Medicine, the BJOG editorial board, the grant review board of the Joint Global Health Trials Initiative from the Wellcome Trust, DfID, MRC and NIHR, and various committees of the World Health Organisation. He is also a Specialist Advisor of the NICE Interventional Procedures Programme, and the founding trustee of Ammalife, a UK-registered charity and leading source of evidence for what works to make childbirth safer in low income countries.